

B9

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 October 2002 (17.10.2002)


PCT

(10) International Publication Number  
**WO 02/081698 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N 15/31**, C07K 14/245, C12P 13/08 // (C12P 13/08, C12R 1:19)
- (21) International Application Number: **PCT/EP02/02420**
- (22) International Filing Date: **6 March 2002 (06.03.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
101 16 518.8      3 April 2001 (03.04.2001)    **DE**
- (71) Applicant: **DEGUSSA AG [DE/DE]**; Bennigsenplatz 1, 40474 Düsseldorf (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors: **RIEPING, Mechthild**; Mönkebergstrasse 1, 33619 Bielefeld (DE). **HERMANN, Thomas**; Zirkonstrasse 8, 33739 Bielefeld (DE).
- Published:**  
— *without international search report and to be republished upon receipt of that report*

[Continued on next page]

(54) Title: PROCESS FOR THE PRODUCTION OF L-AMINO ACIDS USING STRAINS OF THE FAMILY ENTEROBACTERIACEAE THAT CONTAIN AN ATTENUATED FRUR GENE



(57) Abstract: The invention relates to a process for the production of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of the microorganisms of the family Enterobacteriaceae producing the desired L-amino acid, in which the fruR gene or nucleotide sequences coding therefor are attenuated, in particular are switched off, b) enrichment of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.

WO 02/081698 A2



— with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**Process for the Production of L-Amino Acids using  
Strains of the Family Enterobacteriaceae  
that contain an Attenuated fruR Gene**

Field of the Invention

- 5 The present invention relates to a process for the enzymatic production of L-amino acids, in particular L-threonine, using strains of the family Enterobacteriaceae in which the fruR gene is attenuated.

Prior Art

- 10 L-amino acids, in particular L-threonine, are used in human medicine and in the pharmaceutical industry, in the foodstuffs industry, and most especially in animal nutrition.

- It is known to produce L-amino acids by fermentation of strains of Enterobacteriaceae, in particular Escherichia coli (E. coli) and Serratia marcescens. On account of their great importance efforts are constantly being made to improve processes for producing the latter. Process improvements may relate to fermentation technology measures, such as for example stirring and provision of oxygen, or the composition of the nutrient media, such as for example the sugar concentration during the fermentation, or the working-up to the product form, for example by ion exchange chromatography, or the intrinsic performance properties of the microorganism itself.

- Methods comprising mutagenesis, selection and mutant choice are employed in order to improve the performance properties of these microorganisms. In this way strains are obtained that are resistant to antimetabolites, such as for example the threonine analogue  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid (AHV) or are auxotrophic for regulatorily important metabolites, and that produce L-amino acids such as for example L-

threonine.

Methods of recombinant DNA technology have also been used for some years in order to improve strains of the family Enterobacteriaceae producing L-amino acids, by amplifying individual amino acid biosynthesis genes and investigating  
5 their effect on production.

#### Object of the Invention

The object of the invention is to provide new measures for the improved enzymatic production of L-amino acids, in particular L-threonine.

#### 10 Summary of the Invention

The invention provides a process for the enzymatic production of L-amino acids, in particular L-threonine, using microorganisms of the family Enterobacteriaceae that in particular already produce L-amino acids and in which  
15 the nucleotide sequence coding for the fruR gene is attenuated.

#### Detailed Description of the Invention

Where L-amino acids or amino acids are mentioned hereinafter, this is understood to mean one or more amino  
20 acids including their salts, selected from the group comprising L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-  
25 arginine. L-threonine is particularly preferred.

The term "attenuation" describes in this connection the reduction or switching off of the intracellular activity of one or more enzymes (proteins) in a microorganism that are coded by the corresponding DNA, by using for example a weak  
30 promoter or a gene or allele that codes for a corresponding enzyme with a low activity and/or that inactivates the

corresponding enzyme (protein) or gene, and optionally combining these measures.

By means of these attenuation measures the activity or concentration of the corresponding protein is generally  
5 reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild type protein, or the activity or concentration of the protein in the initial microorganism.

The process is characterized in that the following steps  
10 are carried out:

- a) fermentation of microorganisms of the family Enterobacteriaceae in which the fruR gene is attenuated,
- 15 b) enrichment of the corresponding L-amino acid in the medium or in the cells of the microorganisms of the family Enterobacteriaceae, and
- c) isolation of the desired L-amino acid, in which optionally constituents of the fermentation broth and/or the biomass in its entirety or parts thereof  
20 remain in the product.

The microorganisms that are the subject of the present invention can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. The  
25 microorganisms are members of the family Enterobacteriaceae selected from the genera Escherichia, Erwinia, Providencia and Serratia. The genera Escherichia and Serratia are preferred. In the case of the genus Escherichia the species Escherichia coli may in particular be mentioned,  
30 and in the case of the genus Serratia the species Serratia marcescens may in particular be mentioned.

Suitable strains of the genus *Escherichia*, in particular those of the species *Escherichia coli*, that produce in particular L-threonine, include for example:

- Escherichia coli TF427
- 5 Escherichia coli H4578
- Escherichia coli KY10935
- Escherichia coli VNIIGenetika MG442
- Escherichia coli VNIIGenetika M1
- Escherichia coli VNIIGenetika 472T23
- 10 Escherichia coli BKIIM B-3996
- Escherichia coli kat 13
- Escherichia coli KCCM-10132

- Suitable strains of the genus *Serratia*, in particular of the species *Serratia marcescens*, that produce L-threonine
- 15 include for example:

- Serratia marcescens* HNr21
- Serratia marcescens* TLr156
- Serratia marcescens* T2000

- Strains of the family of Enterobacteriaceae producing L-
- 20 threonine preferably have, *inter alia*, one or more of the genetic or phenotype features selected from the following group: resistance to  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to  $\alpha$ -methylserine, resistance to diaminosuccinic
- 25 acid, resistance to  $\alpha$ -aminobutyric acid, resistance to borrelidin, resistance to rifampicin, resistance to valine analogues such as for example valine hydroxamate, resistance to purine analogues such as for example 6-dimethylaminopurine, need for L-methionine, optionally
- 30 partial and compensatable need for L-isoleucine, need for meso-diaminopimelic acid, auxotrophy with regard to threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid,

resistance to L-aspartate, resistance to L-leucine,  
resistance to L-phenylalanine, resistance to L-serine,  
resistance to L-cysteine, resistance to L-valine,  
sensitivity to fluoropyruvate, defective threonine  
5 dehydrogenase, optionally ability to utilise sucrose,  
enhancement of the threonine operon, enhancement of  
homoserine dehydrogenase, I-aspartate kinase I, preferably  
of the feedback-resistant form, enhancement of homoserine  
kinase, enhancement of threonine synthase, enhancement of  
10 aspartate kinase, optionally of the feedback-resistant  
form, enhancement of aspartate semialdehyde dehydrogenase,  
enhancement of phosphoenol pyruvate carboxylase, optionally  
of the feedback-resistant form, enhancement of phosphoenol  
pyruvate synthase, enhancement of transhydrogenase,  
15 enhancement of the RhtB gene product, enhancement of the  
RhtC gene product, enhancement of the YfiK gene product,  
enhancement of a pyruvate carboxylase, and attenuation of  
acetic acid formation.

It has now been found that microorganisms of the family  
20 Enterobacteriaceae after attenuation, in particular after  
switching off the fruR gene, produce L-amino acids, in  
particular L-threonine, in an improved way.

The nucleotide sequences of the Escherichia coli genes  
belong to the prior art and may also be obtained from the  
25 genome sequence of Escherichia coli published by Blattner  
et al. (Science 277, 1453 - 1462 (1997)).

The fruR gene is described *inter alia* by the following  
data:

Designation:	Fructose repressor
30 EC-No.:	-
Reference:	Jahreis et al., Molecular and General Genetics 226, 332-336 (1991)
Accession No.:	AE000118

Comment: The fruR gene is also designated in the prior art as cra gene.

Apart from the described fruR gene, alleles of the gene may be used that result from the degeneracy of the genetic code  
5 or from functionally neutral sense mutations, the activity of the protein not being substantially altered.

In order to achieve an attenuation the expression of the gene or the catalytic properties of the enzyme proteins may for example be reduced or switched off. Optionally both  
10 measures may be combined.

The gene expression may be reduced by suitable culture conditions, by genetic alteration (mutation) of the signal structures of the gene expression, or also by antisense-RNA techniques. Signal structures of the gene expression are  
15 for example repressor genes, activator genes, operators, promoters, attenuators, ribosome-binding sites, the start codon and terminators. The person skilled in the art may find relevant information in, *inter alia*, articles by Jensen and Hammer (Biotechnology and Bioengineering 58:  
20 191-195 (1998)), by Carrier and Keasling (Biotechnology Progress 15, 58-64 (1999)), Franch and Gerdes (Current Opinion in Microbiology 3, 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as for example the textbook by Knippers ("Molekulare Genetik", 6<sup>th</sup>  
25 Edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations that lead to a change or reduction of the catalytic properties of enzyme proteins are known from the  
30 prior art. As examples there may be mentioned the works by Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences, USA 95, 5511-5515 (1998)), Wentz and Schachmann (Journal of Biological Chemistry 266, 20833-



20839 (1991)). Descriptive overviews may be obtained from known textbooks on genetics and molecular biology, such as for example that by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

- 5 Suitable mutations include transitions, transversions, insertions and deletions. Depending on the action of the amino acid exchange on the enzyme activity, one speaks of missense mutations or nonsense mutations. Insertions or deletions of at least one base pair in a gene lead to frame  
10 shift mutations, which in turn lead to the incorporation of false amino acids or the premature termination of a translation. If as a result of the mutation a stop codon is formed in the coding region, this also leads to a premature termination of the translation. Deletions of  
15 several codons typically lead to a complete disruption of the enzyme activity. Details regarding the production of such mutations belong to the prior art and may be obtained from known textbooks on genetics and molecular biology, such as for example the textbook by Knippers ("Molekulare  
20 Genetik", 6<sup>th</sup> Edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).
- 25 Suitable mutations in the genes such as for example deletion mutations may be incorporated by gene and/or allele exchange in suitable strains.

- A conventional method is the method of gene exchange by means of a conditionally replicating pSC101 derivate  
30 pMAK705 described by Hamilton et al. (Journal of Bacteriology 171, 4617 - 4622 (1989)). Other methods described in the prior art, such as for example that of Martinez-Morales et al. (Journal of Bacteriology 181, 7143-7148 (1999)) or that of Boyd et al. (Journal of  
35 Bacteriology 182, 842-847 (2000)) may likewise be used.

It is also possible to transfer mutations in the respective genes or mutations relating to the expression of the relevant genes, by conjugation or transduction into various strains.

- 5 Furthermore for the production of L-amino acids, in particular L-threonine, using strains of the family Enterobacteriaceae it may be advantageous in addition to the attenuation of the fruR gene also to enhance one or more enzymes of the known threonine biosynthesis pathway or  
10 enzymes of anaplerotic metabolism or enzymes for the production of reduced nicotinamide-adenine-dinucleotide phosphate.

- The term "enhancement" describes in this connection the raising of the intracellular activity of one or more  
15 enzymes or proteins in a microorganism that are coded by the corresponding DNA, by for example increasing the number of copies of the gene or genes, using a strong promoter or a gene that codes for a corresponding enzyme or protein having a high activity, and optionally by combining these  
20 measures.

- By means of the aforementioned enhancement measures, in particular overexpression, the activity or concentration of the corresponding protein is in general raised by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%,  
25 at most up to 1000% or 2000% referred to that of the wild type protein and/or the activity or concentration of the protein in the initial microorganism.

- Thus, one or more of the genes selected from the following group may for example be simultaneously enhanced, in  
30 particular overexpressed:

- the thrABC operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),

- the *pyc* gene coding for pyruvate carboxylase (DE-A-19 831 609),
- the *pps* gene coding for phosphoenol pyruvate synthase (Molecular and General Genetics 231:332 (1992)),
- 5 • the *ppc* gene coding for phosphoenol pyruvate carboxylase (Gene 31:279-283 (1984)),
- the genes *pntA* and *pntB* coding for transhydrogenase (European Journal of Biochemistry 158:647-653 (1986)),
- 10 • the gene *rhtB* imparting homoserine resistance (EP-A-0 994 190),
- the *mgo* gene coding for malate:quinone oxidoreductase (DE 100 348 33.5),
- the gene *rhtC* imparting threonine resistance (EP-A-1 013 765), and
- 15 • the *thrE* gene of *Corynebacterium glutamicum* coding for threonine export (DE 100 264 94.8).

The use of endogenous genes is in general preferred. The term "endogenous genes" or "endogenous nucleotide sequences" is understood to mean the genes or nucleotide sequences  
20 present in the population of a species.

Furthermore for the production of L-amino acids, in particular L-threonine, it may be advantageous in addition to the attenuation of the *fruR* gene also to attenuate, in particular to switch off or reduce the expression of one or  
25 more of the genes selected from the following group:

- the *tdh* gene coding for threonine dehydrogenase (Ravnikar and Somerville, Journal of Bacteriology 169, 4716-4721 (1987)),

- the mdh gene coding for malate dehydrogenase (E.C. 1.1.1.37) (Vogel et al., Archives in Microbiology 149, 36-42 (1987)),
- 5 • the gene product of the open reading frame (orf) yjfa (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the gene product of the open reading frame (orf) ytff (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- 10 • the pckA gene coding for the enzyme phosphoenol pyruvate carboxykinase (Medina et al. (Journal of Bacteriology 172, 7151-7156 (1990)),
- the poxB gene coding for pyruvate oxidase (Grabau and Cronan (Nucleic Acids Research 14 (13), 5449-5460
- 15 (1986)),
- the aceA gene coding for isocitrate lyase (EC-No.: 4.1.3.1) (Matsuoko and McFadden; Journal of Bacteriology 170, 4528-4536 (1988) and Accession No.: AE000474), and
- the dgsA gene coding for the regulator of the
- 20 phosphotransferase system (Hosono et al., Bioscience, Biotechnology and Biochemistry 59, 256-261 (1995) and Accession No.: AE000255)

Furthermore for the production of L-amino acids, in particular L-threonine, it may be advantageous in addition

25 to the attenuation of the fruR gene also to switch off undesirable secondary reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

- 30 The microorganisms produced according to the invention may be cultivated in a batch process (batch cultivation), in a

- fed batch process (feed process) or in a repeated fed batch process (repetitive feed process). A summary of known cultivation methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die
- 5 Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Brunswick/Wiesbaden, 1994)).

- The culture medium to be used must appropriately satisfy
- 10 the requirements of the respective strains. Descriptions of culture media of various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

- 15 As carbon sources, sugars and carbohydrates such as for example glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats such as for example soya bean oil, sunflower oil, groundnut oil and coconut oil, fatty acids such as for example
- 20 palmitic acid, stearic acid and linoleic acid, alcohols such as for example glycerol and ethanol, and organic acids such as for example acetic acid, may be used. These substances may be used individually or as a mixture.

- As nitrogen source, organic nitrogen-containing compounds
- 25 such as peptones, yeast extract, meat extract, malt extract, maize steep liquor, soya bean flour and urea or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate may be used. The nitrogen sources may be
- 30 used individually or as a mixture.

As phosphorus source, phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts may be used. The culture medium must furthermore contain salts of metals,

- such as for example magnesium sulfate or iron sulfate, that are necessary for growth. Finally, essential growth promoters such as amino acids and vitamins may be used in addition to the aforementioned substances. Apart from  
5 these, suitable precursors may be added to the culture medium. The aforementioned starting substances may be added to the culture in the form of a single batch or may be metered in in an appropriate manner during the cultivation.
- 10 In order to regulate the pH of the culture basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water, or acidic compounds such as phosphoric acid or sulfuric acid are used as appropriate. In order to control foam formation antifoaming agents such as for  
15 example fatty acid polyglycol esters may be used. In order to maintain the stability of plasmids, suitable selectively acting substances, for example antibiotics, may be added to the medium. In order to maintain aerobic conditions, oxygen or oxygen-containing gas mixtures such as for  
20 example air are fed into the culture. The temperature of the culture is normally 25°C to 45°C, and preferably 30°C to 40°C. Cultivation is continued until a maximum amount of L-amino acids (or L-threonine) has been formed. This target is normally achieved within 10 hours to 160 hours.
- 25 The L-amino acids may be analyzed by anion exchange chromatography followed by ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190), or by reversed phase HPLC, as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167-  
30 1174).

The process according to the invention can be used for the enzymatic production of L-amino acids, such as for example L-threonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-lysine, in particular L-threonine.

A pure culture of the Escherichia coli K-12 strain DH5 $\alpha$ /pMAK705 was filed as DSM 13720 on 8 September 2000 at the German Collection for Microorganisms and Cell Cultures (DSMZ, Brunswick, Germany) according to the Budapest  
5 Convention.

The present invention is described in more detail hereinafter with the aid of examples of implementation.

The isolation of plasmid DNA from Escherichia coli as well as all techniques for the restriction, ligation, Klenow  
10 treatment and alkaline phosphatase treatment are carried out according to Sambrook et al. (Molecular Cloning - A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press). The transformation of Escherichia coli is, unless otherwise described, carried out according to Chung et al.  
15 (Proceedings of the National Academy of Sciences of the United States of America, USA (1989) 86: 2172-2175).

The incubation temperature in the production of strains and transformants is 37°C. In the gene exchange process according to Hamilton et al, temperatures of 30°C and 44°C  
20 are used.

#### Example 1

Construction of the deletion mutation of the fruR gene

Parts of the gene regions and parts of the 5'- and 3'-region of the fruR gene from Escherichia coli K12 lying  
25 upstream and downstream of the fruR gene are amplified using the polymerase chain reaction (PCR) as well as synthetic oligonucleotides. Starting from the nucleotide sequence of the fruR gene and sequences in E. coli K12 MG1655 DNA (SEQ ID No. 1, Accession Number AE000118) lying  
30 upstream and downstream, the following PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

fruR'5'-1: 5' - ATGAATCAGGCGCGTTATCC - 3' (SEQ ID No. 3)

fruR'5'-2: 5' - TTGTCGCTCACACGGTATTG - 3' (SEQ ID No. 4)

fruR'3'-1: 5' - AGCGTGTGCTGGAGATTGTC - 3' (SEQ ID No. 5)

fruR'3'-2: 5' - AGCCAGTCACAAGGCATACC - 3' (SEQ ID No. 6)

The chromosomal E. coli K12 MG1655 DNA used for the PCR is  
5 isolated according to the manufacturer's instructions using  
"Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A  
ca. 750 bp large DNA fragment from the 5' region of the  
fruR gene region (designated fruR1) and a ca. 650 bp large  
DNA fragment from the 3' region of the fruR gene region  
10 (designated as fruR2) may be amplified with the specific  
primers under standard PCR conditions (Innis et al. (1990)  
PCR Protocols. A Guide to Methods and Applications,  
Academic Press) with the taq-DNA-polymerase (Gibco-BRL,  
Eggenstein, Germany). The PCR products are ligated  
15 according to the manufacturer's instructions in each case  
with the vector pCR2.1TOPO (TOPO TA Cloning Kit,  
Invitrogen, Groningen, Netherlands) and transformed in the  
E. coli strain TOP10F'. The selection of plasmid-carrying  
cells is carried out on LB agar to which 50 µg/ml of  
20 ampicillin has been added. After the plasmid DNA isolation  
the vector pCR2.1TOPOfruR2 is cleaved with the restriction  
enzyme NotI and the supernatant 3'-ends are treated with  
Klenow enzyme. After the restriction with the enzyme SpeI  
the fruR2 fragment is separated in 0.8% agarose gel and  
25 isolated using the QIAquick Gel Extraction Kit (QIAGEN,  
Hilden, Germany). After the plasmid DNA isolation, the  
vector pCR2.1TOPOfruR1 is cleaved with the enzymes EcoRV  
and XbaI and ligated with the isolated fruR2 fragment. The  
E. coli strain DH5α is transformed with the ligation batch  
30 and plasmid-carrying cells are selected on LB agar to which  
50 µg/ml of ampicillin has been added. After the plasmid  
DNA isolation those plasmids in which the mutagenic DNA  
sequence illustrated in SEQ ID No. 7 is present in cloned  
form are detected by control cleavage with the enzymes



HindIII, EcoRV and PvuI. One of the plasmids is designated pCR2.1TOPOΔfruR.

### Example 2

Construction of the exchange vector pMAK705ΔfruR

- 5 The fruR allele described in Example 1 is isolated from the vector pCR2.1TOPOΔfruR after restriction with the enzyme EcoO109I, treatment of the supernatant 3'-ends with Klenow enzyme, restriction with the enzyme BamHI and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705
- 10 (Hamilton et al. (1989) Journal of Bacteriology 171, 4617 - 4622) that has been digested with the enzymes HincII and BamHI. The ligation batch is transformed in DH5α and plasmid-carrying cells are selected on LB agar to which 20 μg/ml chloramphenicol had been added. Successful cloning
- 15 is detected after plasmid DNA isolation and cleavage with the enzymes HindIII, BamHI, EcoRV, ScaI and SpeI. The resultant exchange vector pMAK705ΔfruR (= pMAK705deltafruR) is shown in Fig. 1.

### Example 3

- 20 Site-specific mutagenesis of the fruR gene in the E. coli strain MG442

The E. coli strain MG442 producing L-threonine is described in patent specification US-A- 4,278,765 and is filed as CMIM B-1628 at the Russian National Collection for

- 25 Industrial Microorganisms (VKPM, Moscow, Russia).

For the exchange of the chromosomal fruR gene by the plasmid-coded deletion construct, MG442 is transformed with the plasmid pMAK705ΔfruR. The gene exchange is carried out by the selection process described by Hamilton et al.

- 30 (1989) Journal of Bacteriology 171, 4617 - 4622) and is verified by standard PCR methods (Innis et al. (1990) PCR

Protocols. A guide to methods and applications, Academic Press) with the following oligonucleotide primers:

fruR'5'-1: 5' - ATGAATCAGGCGCGTTATCC - 3' (SEQ ID No. 3)

fruR'3'-2: 5' - AGCCAGTCACAAGGCATACC - 3' (SEQ ID No. 6)

- 5 After exchange has been carried out the form of the  $\Delta$ fruR allele illustrated in SEQ ID No. 8 is present in MG442. The resultant strain is designated MG442 $\Delta$ fruR.

#### Example 4

Production of L-threonine using the strain MG442 $\Delta$ fruR

- 10 MG442 $\Delta$ fruR is cultivated on minimal medium having the following composition: 3.5 g/l  $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ , 1.5 g/l  $\text{KH}_2\text{PO}_4$ , 1 g/l  $\text{NH}_4\text{Cl}$ , 0.1 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 2 g/l glucose and 20 g/l agar. The formation of L-threonine is checked in batch cultures of 10 ml that are contained in 100 ml Erlenmeyer
- 15 flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast extract, 10 g/l  $(\text{NH}_4)_2\text{SO}_4$ , 1 g/l  $\text{KH}_2\text{PO}_4$ , 0.5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 15 g/l  $\text{CaCO}_3$ , 20 g/l glucose are inoculated and incubated for 16 hours at 37°C and 180 rpm in an ESR incubator from Kühner AG
- 20 (Birsfelden, Switzerland). 250  $\mu$ l of this preculture are reinoculated in 10 ml of production medium (25 g/l  $(\text{NH}_4)_2\text{SO}_4$ , 2 g/l  $\text{KH}_2\text{PO}_4$ , 1 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.03 g/l  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.018 g/l  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ , 30 g/l  $\text{CaCO}_3$  and 20 g/l glucose) and incubated for 48 hours at 37°C. After incubation the
- 25 optical density (OD) of the culture suspension is measured with an LP2W photometer from the Dr. Lange company (Dusseldorf, Germany) at a measurement wavelength of 660 nm.

- The concentration of formed L-threonine is then determined
- 30 in the sterile-filtered culture supernatant using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany)

- BglIII: restriction endonuclease from *Bacillus globigii*
- ClaI: restriction endonuclease from *Caryophanon latu*
- EcoRI: restriction endonuclease from *Escherichia col*
- 5 • EcoRV: restriction endonuclease from *Escherichia col*
- HindIII: restriction endonuclease from *Haemophilus influenzae*
- KpnI: restriction endonuclease from *Klebsiella pneumoniae*
- 10 • PstI: restriction endonuclease from *Providencia stuartii*
- PvuI: restriction endonuclease from *Proteus vulgari*
- SacI: restriction endonuclease from *Streptomyces achromogenes*
- 15 • SalI: restriction endonuclease from *Streptomyces albus*
- SmaI: restriction endonuclease from *Serratia marcescens*
- SphI: restriction endonuclease from *Streptomyces phaeochromogenes*
- 20 • SspI: restriction endonuclease from *Sphaerotilus species*
- XbaI: restriction endonuclease from *Xanthomonas badrii*
- 25 • XhoI: restriction endonuclease from *Xanthomonas holcicola*

**What is Claimed is:**


1. Process for the production of L-amino acids, in particular L-threonine, wherein the following steps are carried out:
  - 5 a) fermentation of the microorganisms of the family Enterobacteriaceae producing the desired L-amino acid, in which the fruR gene or nucleotide sequences coding therefor are attenuated, in particular are switched off,
  - 10 b) enrichment of the L-amino acid in the medium or in the cells of the microorganisms, and
  - c) isolation of the L-amino acid, in which optionally constituents of the fermentation broth and/or the biomass in its entirety or portions  
15 thereof remain in the product.
2. Process according to claim 1, wherein microorganisms are used in which in addition further genes of the biosynthesis pathway of the desired L-amino acid are enhanced.
- 20 3. Process according to claim 1, wherein microorganisms are used in which the metabolic pathways that reduce the formation of the desired L-amino acid are at least partially switched off.
4. Process according to claim 1, wherein the expression  
25 of the polynucleotide(s) that codes/code for the fruR gene is attenuated, in particular is switched off.
5. Process according to claim 1, wherein the regulatory and/or catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide fruR codes are  
30 reduced.

6. Process according to claim 1, wherein for the production of L-amino acids microorganisms of the family Enterobacteriaceae are fermented in which at the same time one or more of the genes selected from the following group is enhanced, in particular overexpressed:
- 6.1 the thrABC operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
- 6.2 the pyc gene coding for pyruvate carboxylase,
- 6.3 the pps gene coding for phosphoenol pyruvate synthase,
- 6.4 the ppc gene coding for phosphoenol pyruvate carboxylase,
- 6.5 the genes pntA and pntB coding for transhydrogenase,
- 6.6 the gene rhtB imparting homoserine resistance,
- 6.7 the mgo gene coding for malate:quinone oxidoreductase,
- 6.8 the gene rhtC imparting threonine resistance, and
- 6.9 the thrE gene coding for threonine export.
7. Process according to claim 1, wherein for the production of L-amino acids microorganisms of the family Enterobacteriaceae are fermented in which at the same time one or more of the genes selected from the following group is attenuated, in particular switched off, or the expression is reduced:
- 7.1 the tdh gene coding for threonine dehydrogenase,
- 7.2 the adh gene coding for alcohol dehydrogenase,

- 7.3 the gene product of the open reading frame (orf)  
yjfA,
- 7.4 the gene product of the open reading frame (orf)  
ytfP,
- 5 7.5 the pckA gene coding for phosphoenol pyruvate  
carboxykinase,
- 7.6 the poxB gene coding for pyruvate oxidase,
- 7.7 the aceA gene coding for isocitrate lyase,
- 10 7.8 the dgsA gene coding for the regulator of the  
phosphotransferase system.

1/1

Fig. 1:



## SEQUENCE LISTING

5 <110> Degussa AG  
 <120> Process for the production of L-amino acids using strains of the family Enterobacteriaceae containing an attenuated fruR gene  
 10 <130> 020005 BT  
 <160> 8  
 15 <170> PatentIn version 3.1  
 <210> 1  
 <211> 2166  
 <212> DNA  
 <213> Escherichia coli  
 20 <220>  
 <221> CDS  
 <222> (641)..(1645)  
 <223> fruR gene  
 25 <400> 1  
 atgaatcagg cgcgttatcc cgcgtgattg gccttttttc ccagcgtggc tacaacattg 60  
 aaagcctgac cgttgcgcca accgacgacg cgacattatc gcgtatgacc atccagaccg 120  
 30 tgggcatga aaaagtactt gagcagatcg aaaagcaatt acacaaaactg gtcgatgtct 180  
 tgcgcgtgag tgagttgggg cagggcgcg c atgttgagcg ggaaatcatg ctggtgaaaa 240  
 35 ttcaggccag cggttacggg cgtgacgaag tgaaacgtaa tacggaaata ttccgtgggc 300  
 aaattatcga tgcacacccc tcgctttata cggttcaatt agcaggcacc agcggtaagc 360  
 ttgatgcatt tttagcatcg attcgcgatg tggcgaaaat tgtggagggt gtcgctctg 420  
 40 gtgtggtcgg actttcgcgc ggcgataaaa taatgcgttg agaatgatct caatgcgcaa 480  
 tttacagccc aacatgtcac gttgggcttt ttttgcgaaa tcagtgggaa cctggaataa 540  
 45 aagcagttgc cgcagttaat tttctgcgct tagatgttaa tgaatttaac ccataccagt 600  
 acaatggcta tggttttttac attttacgca aggggcaatt gtg aaa ctg gat gaa 655  
 Met Lys Leu Asp Glu  
 1 5  
 50 atc gct cgg ctg gcg gga gtg tcg cgg acc act gca agc tat gtt att 703  
 Ile Ala Arg Leu Ala Gly Val Ser Arg Thr Thr Ala Ser Tyr Val Ile  
 10 15 20  
 55 aac ggc aaa gcg aag caa tac cgt gtg agc gac aaa acc gtt gaa aaa 751  
 Asn Gly Lys Ala Lys Gln Tyr Arg Val Ser Asp Lys Thr Val Glu Lys  
 25 30 35  
 60 gtc atg gct gtg gtg cgt gag cac aat tac cac ccg aac gcc gtg gca 799  
 Val Met Ala Val Val Arg Glu His Asn Tyr His Pro Asn Ala Val Ala  
 40 45 50  
 gct ggg ctt cgt gct gga cgc aca cgt tct att ggt ctt gtg atc ccc 847  
 Ala Gly Leu Arg Ala Gly Arg Thr Arg Ser Ile Gly Leu Val Ile Pro  
 55 60 65



5	gat ctg gag aac acc agc tat acc cgc atc gct aac tat ctt gaa cgc Asp Leu Glu Asn Thr Ser Tyr Thr Arg Ile Ala Asn Tyr Leu Glu Arg 70 75 80 85	895
10	cag gcg cgg caa cgg ggt tat caa ctg ctg att gcc tgc tca gaa gat Gln Ala Arg Gln Arg Gly Tyr Gln Leu Leu Ile Ala Cys Ser Glu Asp 90 95 100	943
15	cag cca gac aac gaa atg cgg tgc att gag cac ctt tta cag cgt cag Gln Pro Asp Asn Glu Met Arg Cys Ile Glu His Leu Leu Gln Arg Gln 105 110 115	991
20	gtt gat gcc att att gtt tgc acg tgc ttg cct cct gag cat cct ttt Val Asp Ala Ile Ile Val Ser Thr Ser Leu Pro Pro Glu His Pro Phe 120 125 130	1039
25	tat caa cgc tgg gct aac gac cgg ttc ccg att gtc gcg ctg gac cgc Tyr Gln Arg Trp Ala Asn Asp Pro Phe Pro Ile Val Ala Leu Asp Arg 135 140 145	1087
30	gcc ctc gat cgt gaa cac ttc acc agc gtg gtt ggt gcc gat cag gat Ala Leu Asp Arg Glu His Phe Thr Ser Val Val Gly Ala Asp Gln Asp 150 155 160 165	1135
35	gat gcc gaa atg ctg gcg gaa gag tta cgt aag ttt ccc gcc gag acg Asp Ala Glu Met Leu Ala Glu Glu Leu Arg Lys Phe Pro Ala Glu Thr 170 175 180	1183
40	gtg ctt tat ctt ggt gcg cta ccg gag ctt tct gtc agc ttc ctg cgt Val Leu Tyr Leu Gly Ala Leu Pro Glu Leu Ser Val Ser Phe Leu Arg 185 190 195	1231
45	gaa caa ggt ttc cgt act gcc tgg aaa gat gat ccg cgc gaa gtg cat Glu Gln Gly Phe Arg Thr Ala Trp Lys Asp Asp Pro Arg Glu Val His 200 205 210	1279
50	ttc ctg tat gcc aac agc tat gag cgg gag gcg gct gcc cag tta ttc Phe Leu Tyr Ala Asn Ser Tyr Glu Arg Glu Ala Ala Ala Gln Leu Phe 215 220 225	1327
55	gaa aaa tgg ctg gaa acg cat ccg atg ccg cag gcg ctg ttc aca acg Glu Lys Trp Leu Glu Thr His Pro Met Pro Gln Ala Leu Phe Thr Thr 230 235 240 245	1375
60	tcg ttt gcg ttg ttg caa gga gtg atg gat gtc acg ctg cgt cgc gac Ser Phe Ala Leu Leu Gln Gly Val Met Asp Val Thr Leu Arg Arg Asp 250 255 260	1423
65	ggc aaa ctg cct tct gac ctg gca att gcc acc ttt ggc gat aac gaa Gly Lys Leu Pro Ser Asp Leu Ala Ile Ala Thr Phe Gly Asp Asn Glu 265 270 275	1471
70	ctg ctc gac ttc tta cag tgt ccg gtg ctg gca gtg gct caa cgt cac Leu Leu Asp Phe Leu Gln Cys Pro Val Leu Ala Val Ala Gln Arg His 280 285 290	1519
75	cgc gat gtc gca gag cgt gtg ctg gag att gtc ctg gca agc ctg gac Arg Asp Val Ala Glu Arg Val Leu Glu Ile Val Leu Ala Ser Leu Asp 295 300 305	1567
80	gaa ccg cgt aag cca aaa cct ggt tta acg cgc att aaa cgt aat ctc Glu Pro Arg Lys Pro Lys Pro Gly Leu Thr Arg Ile Lys Arg Asn Leu 310 315 320 325	1615

tat cgc cgc ggc gtg ctc agc cgt agc taa gccgcgaaca aaaatacgcg 1665  
 Tyr Arg Arg Gly Val Leu Ser Arg Ser  
 330

5 ccaggtgaat ttccctctgg cgcgtagagt acgggactgg acatcaatat gcttaaagta 1725  
 aataagacta ttcttgacta ttattgataa atgcttttaa acccgcccggt taattaactc 1785  
 10 accagctgaa attcacaata attaatgat atcgacagcg cgtttttgca ttattttggt 1845  
 acatgcccgc atgaattgcc gatttaacaa acacttttct ttgcttttgc gcaaaccgcg 1905  
 tggcatcaag cgccacacag acgtaacaag gactgttaac cggggaagat atgtcctaaa 1965  
 15 atgccgctcg cgtcgcaaac tgacacttta tatttgctgt ggaaaatagt gagtcatttt 2025  
 aaaacgggtga tgacgatgag ggattttttc ttacagctat tcataacggt aatttgcttc 2085  
 20 gcacgttgga cgtaaaataa acaacgctga tattagccgt aaacatcggg ttttttacct 2145  
 cggtatgcct tgtgactggc t 2166

<210> 2  
 <211> 334  
 25 <212> PRT  
 <213> Escherichia coli

<400> 2  
 Met Lys Leu Asp Glu Ile Ala Arg Leu Ala Gly Val Ser Arg Thr Thr  
 30 1 5 10 15  
 Ala Ser Tyr Val Ile Asn Gly Lys Ala Lys Gln Tyr Arg Val Ser Asp  
 20 25 30  
 35 Lys Thr Val Glu Lys Val Met Ala Val Val Arg Glu His Asn Tyr His  
 35 40 45  
 Pro Asn Ala Val Ala Ala Gly Leu Arg Ala Gly Arg Thr Arg Ser Ile  
 50 55 60  
 40 Gly Leu Val Ile Pro Asp Leu Glu Asn Thr Ser Tyr Thr Arg Ile Ala  
 65 70 75 80  
 Asn Tyr Leu Glu Arg Gln Ala Arg Gln Arg Gly Tyr Gln Leu Leu Ile  
 45 85 90 95  
 Ala Cys Ser Glu Asp Gln Pro Asp Asn Glu Met Arg Cys Ile Glu His  
 100 105 110  
 50 Leu Leu Gln Arg Gln Val Asp Ala Ile Ile Val Ser Thr Ser Leu Pro  
 115 120 125  
 Pro Glu His Pro Phe Tyr Gln Arg Trp Ala Asn Asp Pro Phe Pro Ile  
 130 135 140  
 55 Val Ala Leu Asp Arg Ala Leu Asp Arg Glu His Phe Thr Ser Val Val  
 145 150 155 160  
 Gly Ala Asp Gln Asp Asp Ala Glu Met Leu Ala Glu Glu Leu Arg Lys  
 60 165 170 175  
 Phe Pro Ala Glu Thr Val Leu Tyr Leu Gly Ala Leu Pro Glu Leu Ser  
 180 185 190  
 65 Val Ser Thr Asp Arg Gln Gln Gly Phe Arg Thr Ala Asp Lys Asp Asp

	195	200	205	
	Pro Arg Glu Val His Phe Leu Tyr Ala Asn Ser Tyr Glu Arg Glu Ala			
	210	215	220	
5	Ala Ala Gln Leu Phe Glu Lys Trp Leu Glu Thr His Pro Met Pro Gln			
	225	230	235	240
10	Ala Leu Phe Thr Thr Ser Phe Ala Leu Leu Gln Gly Val Met Asp Val			
		245	250	255
	Thr Leu Arg Arg Asp Gly Lys Leu Pro Ser Asp Leu Ala Ile Ala Thr			
		260	265	270
15	Phe Gly Asp Asn Glu Leu Leu Asp Phe Leu Gln Cys Pro Val Leu Ala			
		275	280	285
	Val Ala Gln Arg His Arg Asp Val Ala Glu Arg Val Leu Glu Ile Val			
	290	295	300	
20	Leu Ala Ser Leu Asp Glu Pro Arg Lys Pro Lys Pro Gly Leu Thr Arg			
	305	310	315	320
25	Ile Lys Arg Asn Leu Tyr Arg Arg Gly Val Leu Ser Arg Ser			
		325	330	
	<210> 3			
	<211> 20			
	<212> DNA			
30	<213> Artificial sequence			
	<220>			
	<221> Primer			
	<222> (1)..(20)			
35	<223> fruR'5'-1			
	<400> 3			
	atgaatcagg cgcgttatcc			20
40	<210> 4			
	<211> 20			
	<212> DNA			
	<213> Artificial sequence			
45	<220>			
	<221> Primer			
	<222> (1)..(20)			
	<223> fruR'5'-2			
50	<400> 4			
	ttgtcgctca cacggtattg			20
	<210> 5			
	<211> 20			
55	<212> DNA			
	<213> Artificial sequence			
	<220>			
	<221> Primer			
60	<222> (1)..(20)			
	<223> fruR'3'-1			
	<400> 5			
65	agcgtgtgct ggagattgtc			20

5 <210> 6  
 <211> 20  
 <212> DNA  
 <213> Artificial sequence  
 <220>  
 <221> Primer  
 <222> (1)..(20)  
 <223> fruR'3'-2  
 10 <400> 6  
 agccagtcac aaggcataacc 20  
 <210> 7  
 15 <211> 1512  
 <212> DNA  
 <213> Escherichia coli  
 <220>  
 20 <221> misc\_feature  
 <222> (1)..(1512)  
 <223> Mutagenic DNA  
 <220>  
 25 <221> misc\_feature  
 <222> (1)..(42)  
 <223> Technical DNA/ remainder polylinker sequence  
 <220>  
 30 <221> misc\_feature  
 <222> (43)..(780)  
 <223> Part of the upstream-lying region and part of the 5'-region of the fruR gene  
 <220>  
 35 <221> misc\_feature  
 <222> (781)..(837)  
 <223> Technical DNA/ remainder polylinker sequence  
 <220>  
 40 <221> misc\_feature  
 <222> (838)..(1471)  
 <223> Part of the 3'-region of the fruR gene and part of the downstream-lying region  
 45 <220>  
 <221> misc\_feature  
 <222> (1472)..(1512)  
 <223> Technical DNA/ remainder polylinker sequence  
 50 <400> 7  
 gatccactag taacggccgc cagtgtgctg gaattcgccc ttatgaatca ggcgcggttat 60  
 cccgcgtgat tggccttttt tcccagcgtg gctacaacat tgaaagcctg accggttgcgc 120  
 55 caaccgacga tccgacatta tcgcgtatga ccattccagac cgtgggagat gaaaaagtac 180  
 ttgagcagat cgaaaagcaa ttacacaaac tggtcgatgt cttgcgcgtg agtgagttgg 240  
 60 ggcagggcgc gcatgttgag cgggaaatca tgctggtgaa aattcaggcc agcggttacg 300  
 ggcgtgacga agtgaaacgt aatacggaaa tattccgtgg gcaaattatc gatgtcacac 360  
 cctcgcttta taccgttcaa ttagcaggca ccagcggtaa gcttgatgca tttttagcat 420  
 65

```

cgattcgcga tgtggcgaaa attgtggagg ttgctcgctc tgggtgtggtc ggacttttcgc 480
gcgggcgataa aataatgcgt tgagaatgat ctcaatgcgc aatttacagc ccaacatgtc 540
5 acgttgggct ttttttgcga aatcagtgagg aacctggaat aaaagcagtt gccgcagtta 600
attttctgcg cttagatggt aatgaattta acccatacca gtacaatggc tatggttttt 660
acatttttacg caaggggcaa ttgtgaaact ggatgaaatc gctcggctgg cgggagtgtc 720
10 gcggaccact gcaagctatg ttattaacgg caaagcgaag caataccgtg tgagcgacaa 780
aagggcgaat tctgcagatg gccgccagtg tgatggatat ctgcagaatt cgcccttagc 840
15 gtgtgctgga gattgtcctg gcaagcctgg acgaaccgag taagccaaaa cctggtttta 900
cgcgcattaa acgtaatctc tatcgccgag gcgtgctcag ccgtagctaa gccgcgaaca 960
aaaatacgcg ccaggtgaat ttccctctgg cgcgtagagt acgggactgg acatcaatat 1020
20 gcttaaagta aataagacta ttctgacta ttattgataa atgcttttaa acccgccgt 1080
taattaactc accagctgaa attcacaata attaagtgat atcgacagcg cgtttttgca 1140
25 ttattttgtt acatgcggcg atgaattgcc gatttaacaa acacttttct ttgcttttgc 1200
gcaaaccgag tggcatcaag cgccacacag acgtaacaag gactgttaac cggggaagat 1260
atgtcctaaa atgccgctcg cgtcgcaaac tgacacttta ttttgcgtgt ggaaaatagt 1320
30 gagtcatttt aaaacggtga tgacgatgag ggattttttc ttacagctat tcataacgtt 1380
aatttgcttc gcacgttgga cgtaaaataa acaacgctga tattagccgt aaacatcggg 1440
35 ttttttacct cggtatgcct tgtgactggc taagggcgaa ttccagcaca ctggcggccg 1500
ttactagagg gc 1512

```

```

40 <210> 8
    <211> 268
    <212> DNA
    <213> Escherichia coli

```

```

45 <220>
    <221> misc_feature
    <222> (1)..(268)
    <223> Mutagenic DNA

```

```

50 <220>
    <221> misc_feature
    <222> (1)..(3)
    <223> Start codon of the delta fruR allele

```

```

55 <220>
    <221> misc_feature
    <222> (1)..(98)
    <223> 5'-region of the delta fruR allele

```

```

60 <220>
    <221> misc_feature
    <222> (99)..(155)
    <223> Technical DNA/ remainder polylinker sequence

```

```

65 <220>
    <221> misc_feature

```

```
<222> (156)..(265)
<223> 3'-region of the delta fruR allele

<220>
5 <221> misc_feature
  <222> (266)..(268)
  <223> Stop codon of the delta fruR allele

<400> 8
10 gtgaaactgg atgaaatcgc tcggctggcg ggagtgtcgc ggaccactgc aagctatggt 60
   attaacggca aagcgaagca ataccgtgtg agcgacaaaa ggcgaattc tgcagatggc 120
   cgccagtgtg atggatatct gcagaattcg cccttagcgt gtgctggaga ttgtcctggc 180
15 aagcctggac gaaccgcgta agccaaaacc tggtttaacg cgcattaaac gtaatctcta 240
   tcgccgcggc gtgctcagcc gtagctaa 268
20
```

PCT


020005 BT

Original (for SUBMISSION) - printed on 05.03.2002 09:02:18 AM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	020005 BT

1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	13
1-2	line	1-5
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	08 September 2000 (08.09.2000)
1-3-4	Accession Number	DSMZ 13720
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications  These indications will be submitted to the International Bureau later	NONE

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	yes
0-4-1	Authorized officer	 C.A.J.A. PASCHE

## FOR INTERNATIONAL BUREAU USE ONLY


0-5	This form was received by the international Bureau on:	
0-5-1	Authorized officer	

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Degussa-Hüls AG  
Kantstr. 2  
33790 Halle

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:  DH5 $\alpha$ /pMAK705	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 13720
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I. above was accompanied by:  <div style="margin-left: 40px;"> <input checked="" type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation         </div> (Mark with a cross where applicable).	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2000-09-08 (Date of the original deposit) <sup>1</sup> .	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2000-09-12

<sup>1</sup> Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.



BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

PCT/EP02/02420

INTERNATIONAL FORM


Degussa-Hüls AG  
Kantstr. 2  
33790 Halle

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the

INTERNATIONAL DEPOSITARY AUTHORITY

Identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa-Hüls AG Kantstr. 2 Address: 33790 Halle	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 13720  Date of the deposit or the transfer <sup>1</sup> : 2000-09-08
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 2000-09-08 <sup>2</sup> . On that date, the said microorganism was  <input checked="" type="checkbox"/> viable  <input type="checkbox"/> no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED <sup>4</sup>	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2000-09-12

<sup>1</sup> Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

<sup>2</sup> In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

<sup>3</sup> Mark with a cross the applicable box.

<sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number  
**WO 02/081698 A3**

(51) International Patent Classification<sup>7</sup>: **C12P 13/08**,  
13/04 // (C12P 13/08, C12R 1:19)

(21) International Application Number: **PCT/EP02/02420**

(22) International Filing Date: **6 March 2002 (06.03.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**101 16 518.8** **3 April 2001 (03.04.2001)** **DE**

(71) Applicant: **DEGUSSA AG** [DE/DE]; Bennigsenplatz 1,  
40474 Düsseldorf (DE).

(72) Inventors: **RIEPING, Mechthild**; Mönkebergstrasse 1,  
33619 Bielefeld (DE). **HERMANN, Thomas**; Zirkon-  
strasse 8, 33739 Bielefeld (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).


**Published:**

- with international search report
- with (an) indication(s) in relation to deposited biological  
material furnished under Rule 13bis separately from the  
description

(88) Date of publication of the international search report:  
**30 October 2003**

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **PROCESS FOR THE PRODUCTION OF L-AMINO ACIDS USING STRAINS OF THE FAMILY ENTEROBACTE-  
RIACEAE THAT CONTAIN AN ATTENUATED fruR GENE**



(57) Abstract: The invention relates to a process for the production of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of the microorganisms of the family Enterobacteriaceae producing the desired L-amino acid, in which the fruR gene or nucleotide sequences coding therefor are attenuated, in particular are switched off, b) enrichment of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.

02/081698 A3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/02420

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12P13/08 C12P13/04 //(C12P13/08,C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12P C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 53035 A (ALTMAN ELLIOT ;GOKARN RAVI R (US); EITEMAN MARK A (US); UNIV GEORG) 21 October 1999 (1999-10-21) page 5, line 20-24 examples 4,7,9,10 claims 41,49 figures 1,4	1-7
Y	RAMSEIER T M: "Cra and the control of carbon flux via metabolic pathways." RESEARCH IN MICROBIOLOGY, vol. 147, no. 6-7, July 1996 (1996-07), pages 489-493, XP002241023 ISSN: 0923-2508 the whole document figure 1	1-7
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

20 May 2003

Date of mailing of the international search report

02/06/2003

Name and mailing address of the ISA  
European Patent Office, P.O. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 240-2140, Tlx. 51 951 630 nl,  
Fax: (+31-70) 240-2016

Authorized officer

## INTERNATIONAL SEARCH REPORT


International Application No

PC1/EP 02/02420

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JAHREIS K ET AL.: "Nucleotide sequence of the <i>ilvH-fruR</i> gene region of <i>Escherichia coli</i> K12 and <i>Salmonella typhimurium</i> LT2" MOLECULAR AND GENERAL GENETICS, vol. 226, no. 1/2, April 1991 (1991-04), pages 332-336, XP002937889 ISSN: 0026-8925 cited in the application the whole document	1-7
A	MICHAL G: "Biochemical pathways: an atlas of biochemistry and molecular biology" 1999, JOHN WILEY & SONS INC. AND SPEKTRUM AKADEMISCHER VERLAG, NEW YORK - HEIDELBERG XP002240819 ISBN: 0-471-33130-9 figures 3.8-1 and 3.8-2 figures 4.2-1, 4.5-1 and 4.5-2 paragraph 4.5.3!	1-7
A	KRAEMER R: "Genetic and physiological approaches for the production of amino acids" JOURNAL OF BIOTECHNOLOGY, vol. 45, no. 1, 1996, pages 1-21, XP002178648 ISSN: 0168-1656 the whole document	1-7
A	US 4 278 765 A (DEBBOV VLADIMIR G ET AL) 14 July 1981 (1981-07-14) cited in the application the whole document	1-7
A	EP 0 643 135 A (AJINOMOTO KK) 15 March 1995 (1995-03-15) the whole document	1-7
A	EP 0 237 819 A (KYOWA HAKKO KOGYO KK) 23 September 1987 (1987-09-23) the whole document	1-7
A	DATABASE WPI Section Ch, Week 199148 Derwent Publications Ltd., London, GB; Class B05, AN 1991-351136 XP002241222 & JP 03 236786 A (KYOWA HAKKO KOGYO KK), 22 October 1991 (1991-10-22) abstract	1-7

-/--

# INTERNATIONAL SEARCH REPORT

Intern  Application No  
PCT/EP 02/02420

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 952 221 A (AJINOMOTO KK) 27 October 1999 (1999-10-27) page 2, line 24 -page 3, line 2 page 6, line 42 -page 7, line 6 claim 1	1-7
A	EP 0 955 368 A (AJINOMOTO KK) 10 November 1999 (1999-11-10) page 2, line 22-56 page 6, line 9-31 claim 6	1-7
A	JETTEN M S M ET AL.: "Recent advances in the physiology and genetics of amino acid-producing bacteria." CRC CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 15, no. 1, 1995, pages 73-103, XP000613291 ISSN: 0738-8551 figure 1 page 90, left-hand column, line 1 -page 92, left-hand column, line 17	1-7
A	SAWERS G: "The anaerobic degradation of L-serine and L-threonine in enterobacteria: networks of pathways and regulatory signals" ARCHIVES OF MICROBIOLOGY, vol. 171, no. 1, 1998, pages 1-5, XP002953871 ISSN: 0302-8933 the whole document	1-7
E	WO 02 081721 A (DEGUSSA) 17 October 2002 (2002-10-17) the whole document page 9, line 24 -page 10, line 25 claim 7	1-7
E	WO 02 081722 A (DEGUSSA) 17 October 2002 (2002-10-17) the whole document page 9, line 21 -page 10, line 22 claim 7	1-7

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 02/02420

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9953035	A	21-10-1999	AU 3555999 A BR 9909615 A CA 2325598 A1 EP 1073722 A1 JP 2002511250 T WO 9953035 A1 US 2003087381 A1 US 6455284 B1	01-11-1999 12-12-2000 21-10-1999 07-02-2001 16-04-2002 21-10-1999 08-05-2003 24-09-2002
US 4278765	A	14-07-1981	SU 875663 A1 HU 190999 B	15-09-1982 28-12-1986
EP 0643135	A	15-03-1995	AT 203769 T CZ 9401658 A3 DE 69330518 D1 DE 69330518 T2 DK 643135 T3 EP 0643135 A1 JP 3331472 B2 SK 81994 A3 US 5661012 A EP 1020526 A2 ES 2158867 T3 WO 9411517 A1 RU 2113484 C1	15-08-2001 15-12-1994 06-09-2001 08-05-2002 15-10-2001 15-03-1995 07-10-2002 10-05-1995 26-08-1997 19-07-2000 16-09-2001 26-05-1994 20-06-1998
EP 0237819	A	23-09-1987	DE 3788583 D1 DE 3788583 T2 EP 0237819 A2 JP 2574786 B2 JP 63273487 A KR 9108634 B1 US 5017483 A	10-02-1994 19-05-1994 23-09-1987 22-01-1997 10-11-1988 19-10-1991 21-05-1991
JP 3236786	A	22-10-1991	JP 2877414 B2	31-03-1999
EP 0952221	A	27-10-1999	AU 756507 B2 AU 2122399 A BR 9901173 A CN 1233660 A EP 0952221 A2 JP 2000189169 A PL 332072 A1 US 6331419 B1 US 2001019836 A1	16-01-2003 30-09-1999 28-03-2000 03-11-1999 27-10-1999 11-07-2000 27-09-1999 18-12-2001 06-09-2001
EP 0955368	A	10-11-1999	AU 746542 B2 AU 2122499 A BR 9901174 A CN 1233661 A EP 0955368 A2 JP 2000106869 A PL 332071 A1 RU 2188236 C2 US 6197559 B1 US 2002004231 A1	02-05-2002 30-09-1999 28-03-2000 03-11-1999 10-11-1999 18-04-2000 27-09-1999 27-08-2002 06-03-2001 10-01-2002
WO 02081721	A	17-10-2002	DE 10116518 A1	17-10-2002

# INTERNATIONAL SEARCH REPORT

Annex to the International Search Report  
on patent family members

International Application No.

PCT/EP 02/02420

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02081721 A		WO 02081721 A2	17-10-2002
		WO 02081698 A2	17-10-2002
		WO 02081722 A2	17-10-2002
		US 2003054503 A1	20-03-2003
		US 2003059903 A1	27-03-2003
WO 02081722 A	17-10-2002	DE 10116518 A1	17-10-2002
		WO 02081721 A2	17-10-2002
		WO 02081698 A2	17-10-2002
		WO 02081722 A2	17-10-2002
		US 2003054503 A1	20-03-2003
		US 2003059903 A1	27-03-2003